Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News hit the wires dude!!!
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11 2024 - 09:00AM
Share On Facebook
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body.
Proof-of-concept studies to date suggest that Akribion’s G-dase E ribonucleoprotein complexes could be conjugated to TransCode’s TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.
Akribion’s Co-Chief Executive Officer, Lukas Linnig, commented, “We are excited about deepening our relationship with TransCode. Together we have now shown that we can successfully synthesize constructs combining TransCode’s TTX platform and our G-dase E nuclease, demonstrating initial laboratory evidence of efficacy in cancer cells. We look forward to continuing to pursue a combined technology for developing highly targeted drugs to treat cancer.”
Zdravka Medarova, PhD, TransCode Chief Scientific Officer, added, “Establishing proof-of- concept is a critical step in advancing our collaboration. We are fully committed to continuing our joint efforts to developing this technology.”
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
It’s no hype dude!! AI bomb news will hit international news wires hard!!!!
Great call dude!!! Get ready for blue skies up ahead!!!!
Don’t look up dude!!! Blue skies up ahead!!! Strap on your seatbelts dude!!!
FOXO MEDICAL REVOLUTION COMING$$$$$
GO FOXO GO BIG OR GO HOME https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783344/
Monday morning pre market explosion$$$ Have a great weekend
He’s counting his cash in the cayman islands😂😂😂😂
News will hit tomorrow morning dudes!!!!
Next leg lift off !!!!!! Gooooooooooo NXU
Dippppppp is in boys, get ready to ripppppp!!!!
Blue skies coming dude!!!! Sharks smell blood!!!
It’s a rat attack dude!!!
Breakthrough coming in switzerland TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06 2024
The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets. It is expected that delegates from leading companies in these areas will be in attendance.
Details of the Presentation
Stream: Short RNA Based Therapeutics
Title: A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials
Date and Time: March 14th 2:10 p.m. local time
Dr. Medarova’s presentation will describe work completed in support of the TransCode’s ongoing Phase 0 microdose clinical study with its lead therapeutic candidate, TTX-MC138. TTX-MC138 is designed to be delivered to metastatic tumor cells where it is intended to inhibit miR-10b, generally regarded as a master regulator of metastatic disease. In preclinical studies, TTX-MC138 elicited complete responses and life-long disease remission in animal models of adenocarcinoma.
Nonclinical studies to be presented include dosimetry, pharmacokinetics (PK), tissue distribution, and metabolite analysis. In addition, preliminary clinical results including pharmacokinetics and accumulation of the drug candidate in clinical metastases, as well as drug candidate stability, will be discussed. The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.
“We are honored to join key stakeholders in the field of RNA to exchange ideas, share compelling data, and ultimately help further this potentially important technology,“ said Medarova. Dr. Medarova continued, “We believe that TTX-MC138 has the potential to help cancer patients as a first-in-class RNA-based treatment for metastatic disease. We are eager to share our progress with the broader scientific community.”
For more information, please visit:
www.transcodetherapeutics.com and https://informaconnect.com/rna-leaders-europe/
About TransCode
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Evan Gappelberg’s Nex Tech 3d ai is the next Nvidia!! Go Nasdaq go!!!
Hell is where the dirty rat belongs
Hell yes dude!!!!
ARWYF Massive news dudes!!!
ARway.ai Signs Multiple SaaS Deals For its Augmented Reality Experience Platform; in Real Estate, Fashion and Hospitality
Press Release | 03/07/2024
TORONTO, ON / ACCESSWIRE / March 7, 2024 / ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce new partnerships with leading innovators in the industry, Holition.com, 3D Marx and Aigentless. ARway.ai is quickly becoming the preferred choice among industry developers, following successful pilots and established credibility, and these subscriptions signify a major ramp-up in XR project adoption across various sectors.
These subscriptions represent a leap forward in the adoption of AR/VR/XR technologies for location based mobile applications, showcasing a commitment to pushing the boundaries of spatial computing, marketing, and advertising.
Holition.com - UK
Holition is a London-based innovator, crafting bespoke AR, VR, and XR solutions for art, beauty, fashion, and retail sectors. Their expertise in creating captivating digital experiences has set them apart as leaders in immersive technology.
Holition has worldwide notable and luxurious brand clients including Rolls Royce, Tommy Hilfiger, Burberry, Tiffany&Co, Hermes, Moncler, Christian Loubiton and more who are all looking to incorporate immersive technologies like AR/VR/XR into their marketing and branding efforts, as evident through past projects. The ARway platform will be an additional tool to deliver customer projects. View previous projects - click here
3D Marx - UAE
Under this partnership, 3D Marx will integrate ARway's cutting-edge indoor navigation and advertising solutions into their service offerings. This collaboration aims to enhance customer experiences in the retail and hospitality industries, including shopping malls, stores, hotels, resorts, and tourism, thereby elevating the standard of immersive customer engagement.
Located in Dubai, 3D Marx offers unique 3D immersive virtual tours, enhancing customer interaction and engagement through advanced 3D technology. Their services cater to a wide array of industries, fostering a more connected and interactive world.
Aigentless - USA
Aigentless is a dynamic startup located in the United States that is disrupting the real estate market. Their application serves as a matchmaking platform, connecting potential tenants with real estate agents for property showings. Aigentless has chosen to integrate ARway's technology to enhance their upcoming MVP, promising a unique augmented reality experience for property showings. Aigentless is similar to well known real estate industry websites such as rent.ca, realtor.ca, zillow.com.
By leveraging the ARwayKit SDK, Aigentless aims to transform property tours into immersive journeys. Users will benefit from AR navigation to guide them to the right property spaces while highlighting key features and amenities through engaging AR visuals. This innovative approach, focusing on both commercial and residential properties, is expected to set new standards in real estate engagement and customer satisfaction.
Watch a video demo example of ARway's technology for a real estate use case: click here
This deal follows recent news of a new deal signed with DesignSA.me, based in Saudi Arabia. DesignSA.me is at the forefront of providing technology and consulting services for government projects. Their work spans various sectors, including sustainability, defense, energy, and exhibitions. By incorporating the ARwayKit SDK, DesignSA.me plans to introduce augmented reality into multiple government applications, enhancing the efficiency and effectiveness of public services.
To learn more about ARway, please follow on Social Media: Twitter, YouTube, Instagram, LinkedIn, and Facebook, and visit our website: www.arway.ai
About ARway.ai
ARway.ai (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is a spatial computing platform powered by artificial intelligence (AI) providing an array of augmented reality (AR) experiences for indoor spaces. ARway's breakthrough no-code no-beacon IPN allows for the easy creation of navigation, tours, information sharing, notifications, advertising and gamification. ARway works seamlessly as a cross platform solution on iOS/ Android. ARway's technology is optimized for both mobile devices and AR glasses: Apple's Vision Pro, Magic Leap and Microsoft's HoloLens. ARway has unlimited use cases for augmenting physical spaces, making it a valuable tool for creators, brands and companies in various industries. The complete ARway platform includes: the Web Creator Studio, the ARwayKit Software Development Kit (SDK) and a mobile app for iOs and Android.
Nextech 3D.ai
On October 26, 2022, ARway.ai. was spun-out from its parent Company, Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:1SS). Nextech retained a control ownership in ARway.ai. with 13 million shares, or a 50% stake. Nextech3D.ai is a Generative AI powered 3D modeling Company and leading provider of augmented reality ("AR") experience technologies and 3D model services. Nextech's AI-powered 3D modeling platform, "ARitize3D" has contracts with; AMZN, KSS, CB2, Genuine Parts & many others. To learn more about Nextech3D.ai, visit www.nextechar.com
For further information, please contact:
Investor Relations Contact
Julia Viola
investor.relations@arway.ai
ARway.ai
Evan Gappelberg
CEO and Director
866-ARITIZE (274-8493)
Will this collapse to 1$
Stick around dude!!! we in switzerland baby!!!
Hold on to your dirty underwears dude!!!
Take out the news and smoke the rat out of his hole!!!
Hell yes dude!!!! Looking good!!!
Seems like you are obsessed with claudio dude!!! Are you jealous of him?? Do you want to be like claudio?? Seems like your a creep dude!!
Great DD dude!!! Pop your pills strap on your 12’ dildo your going to fly!!!!
CEO Evans with shock the AI World dudes!!!
Huge contract coming,,,,, Take out the news Evans You can do it dude!!!
It’s already QX dude!! Nasdaq next!!!!
Nice call dude!!! $1 News coming with Nasdaq bomb news!!!
Atomic news is coming dudes!!! stay tuned for blue skies!!!
Ring the Nasdaq bell Evan Gooooooo NEXCF!!!!
NEXCF Is The Next Nvidia dudes.. Mark it….explosion coming in record sales!!!!
NEXCF Nextech3D AI Breakout
Time to reload dude!!!! Massive move is coming!!!
Get them dude!!! Don’t forget to pop your pills and fly!!!!
All aboard!!!!!!!Lift off to International space station
There’s the dipppppppp dude!!!!! Now get ready
Needs some rocket fuel dude!!!
Pop your pills and strap on your dildo dude!!!! Your going to fly off the 2x flop ponte with the martone st floppers